SCHEMBL6295486

SCHEMBL6295486

N[C@@H](CCC(=O)O)C(=O)c1ccc(CSc2ccc3c(c2)OCC(=O)N3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
DRD2 P14416 3/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 3/20 0.37
ALDH1A1 P00352 3/20 0.37
GAA P10253 1/20 0.37
PKM P14618 2/20 0.36
TSHR P16473 1/20 0.36
DHFR P00374 1/20 0.35
NSD2 O96028 1/20 0.35
PARP1 P09874 1/20 0.35
HTR1A P08908 1/20 0.34
CHRM5 P08912 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
HTR2A P28223 1/20 0.34
ADRA1B P35368 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301560 0.89 ALDH1A1 (0.39) MAPTRXFP1MEN1KMT2ADRD2
SCHEMBL6301580 0.82 MAPT (0.39) MAPTRXFP1MEN1KMT2ADRD2
SCHEMBL6295838 0.78 PARP1 (0.45) MAPTDRD2DRD4DRD3ALDH1A1
SCHEMBL6297055 0.77 DRD2 (0.51) MAPTRXFP1DRD2DRD4DRD3
SCHEMBL6427774 0.75 DRD4 (0.56) MAPTMEN1KMT2ADRD2DRD4
SCHEMBL6423398 0.73 TRPV1 (0.49) DRD2DRD4DRD3PARP1HTR1A
SCHEMBL6297054 0.73 DRD4 (0.58) MAPTKMT2ADRD2DRD4DRD3
SCHEMBL6329957 0.70 DRD4 (0.53) MAPTDRD2DRD4DRD3ALDH1A1
SCHEMBL6717655 0.70 DRD4 (0.50) MAPTDRD2DRD4DRD3ALDH1A1
SCHEMBL20424472 0.68 DRD4 (0.55) MAPTDRD2DRD4DRD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US disclosed
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2004-06-24 US disclosed
EP-1385835-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS Astrazeneca AB (SE) 2004-02-04 EP disclosed
WO-2002085868-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS ASTRAZENECA AB (SE) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122006-A1 Benzoxazinone derivatives for use in the treatment of angiogenesis HAX1, VEGFA, HYOU1 MAPT 4831/4885RXFP1 90/4885MEN1 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.